Cited by 1,309Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Open access

Garon, Edward B, Ciuleanu, Tudor-Eliade, Arrieta, Oscar, Prabhash, Kumar, Syrigos, Konstantinos N, Goksel, Tuncay, Park, Keunchil, Gorbunova, Vera, Kowalyszyn, Ruben Dario, Pikiel, Joanna, Czyzewicz, Grzegorz, Orlov, Sergey V, Lewanski, Conrad R, Thomas, Michael, Bidoli, Paolo, Dakhil, Shaker, Gans, Steven, Kim, Joo-Hang, Grigorescu, Alexandru, Karaseva, Nina, Reck, Martin, Cappuzzo, Federico, Alexandris, Ekaterine, Sashegyi, Andreas, Yurasov, Sergey, Pérol, Maurice·2014·The Lancet

DOI 10.1016/s0140-6736(14)60845-x

Open this paper in CoChat — free account

Abstract

Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973.Findings Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care.Interpretation Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.Funding Eli Lilly.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60845-x

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer statistics, 2012
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs, C., Tomášek, J., Cho, J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. D., Aprile, G., Ferry, D., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,031
Self-citation
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948

Show all 35 references

Research works printed but not linked: 1

Wilke, 2014, J Clin Oncol, 32

Sorted by citations

Items 601–700 of 1,001

Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non–Small-cell Lung Cancer
Gandara, D. R., Riess, J. W., Kelly, K. L., Li, T., Mack, P. C., & Lara, P. N. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.011 · Cited by 12
LUBAC promotes angiogenesis and lung tumorigenesis by ubiquitinating and antagonizing autophagic degradation of HIF1α
Jin, Y. H., Peng, Y., Xu, J., Yuan, Y., Yang, N., Zhang, Z., Xu, L., Li, L., Xiong, Y., Sun, D., et al. (2024) · Oncogenesis · doi:10.1038/s41389-024-00508-3 · Cited by 12
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial
Pu, X., Xiao, Z., Li, J., Wu, Z., Ma, Z., Weng, J., Xiao, M., Chen, Y., Cao, Y., Cao, P., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107538 · Cited by 11
Atezolizumab and nintedanib in patients with non-small cell lung cancer and interstitial lung disease
Yamaguchi, T., Shimizu, J., Shigematsu, F., Watanabe, N., Hasegawa, T., Horio, Y., Inaba, Y., & Fujiwara, Y. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-45 · Cited by 11
Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives
Zhang, H., Zhang, Y., Zhu, Y., Dong, T., & Liu, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1387345 · Cited by 14
CT-based deep learning radiomics biomarker for programmed cell death ligand 1 expression in non-small cell lung cancer
Xu, T., Liu, X., Chen, Y., Wang, S., Jiang, C., & Gong, J. (2024) · BMC Medical Imaging · doi:10.1186/s12880-024-01380-8 · Cited by 13
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study
Zhou, Q. H., Yang, N., Zhao, M., Huang, D., Zhao, J., Yu, Y., Yuan, Y., Sun, L., Dong, X., Zhang, T., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114337 · Cited by 11
Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer
Daum, S., Decristoforo, L., Mousa, M., Salcher, S., Plattner, C., Hosseinkhani, B., Trajanoski, Z., Wolf, D. G. F., Carmeliet, P., & Pircher, A. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02221-6 · Cited by 12
Recent advances in therapeutic targeting of the KRAS pathway in cancer
Hitchen, N., Williams, S., & Desai, J. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108889 · Cited by 15
The role of angiogenesis inhibitors in the treatment of elderly patients with advanced non-small-cell lung cancer: A meta-analysis of eleven randomized controlled trials
Tian, R.-H., Wu, X., Liu, X., Yang, J.-W., Ji, H.-L., & Yan, Y. (2016) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.151950 · Cited by 11
Milestones in the systemic treatment of lung cancer
Pirker, R. (2017) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-017-0313-9 · Cited by 11
Pre-existing interstitial lung disease as a risk factor for pneumonitis associated with ramucirumab and paclitaxel in patients with gastric cancer: The impact of usual interstitial pneumonia
Koyama, N., Katayanagi, S., & Kawachi, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198886 · Cited by 11
Antibody drug conjugates in thoracic malignancies
Pacheco, J. M., & Camidge, D. R. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.001 · Cited by 12
Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma
Zeng, D., Lei, W., Wang, C., Huang, J., & Jiang, J. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3743-0 · Cited by 11
New options for combination therapy for advanced non-squamous NSCLC
Rossi, A. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1667233 · Cited by 11
Changing paradigm in advanced and metastatic non-small cell lung cancer
Uprety, D., Parikh, K., Sawkar, A., Dimou, A., & Leventakos, K. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1472 · Cited by 10
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
Nadal, E., Horinouchi, H., Shih, J., Nakagawa, K., Reck, M., Garon, E. B., Wei, Y., Kollmeier, J., Frimodt‐Moller, B., Barrett, E., et al. (2021) · Drug Safety · doi:10.1007/s40264-021-01127-2 · Cited by 11
Self-citation
Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma
Feng, W., Lin, A., Sun, L., Wei, T., Ying, H., Zhang, J., Luo, P., & Zhu, W. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02604-z · Cited by 10
Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review
Wang, Y., Wang, B., Xiang, L., Deng, J., Xu, B., He, P., Pu, W., Wang, H., Fan, Y., & Chen, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016647 · Cited by 9
Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers
Genova, C., Rijavec, E., & Grossi, F. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1121112 · Cited by 11
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
Ramalingam, S. S., Pérol, M., Reck, M., Kowalyszyn, R. D., Gautschi, O. P., Kimmich, M., Cho, E. K., Czyżewicz, G., Grigorescu, A. C., Karaseva, N. A., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.12.011 · Cited by 11
Self-citation
Apatinib for advanced nonsmall-cell lung cancer
Yang, C., Feng, W. M., & Wu, D. (2018) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_258_17 · Cited by 11
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
Yen, C.-J., Muro, K., Kim, T.-W., Kudo, M., Shih, J., Lee, K., Chao, Y., Kim, S.-W., Yamazaki, K., Sohn, J., et al. (2018) · Journal of Global Oncology · doi:10.1200/jgo.17.00227 · Cited by 11
Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer
Pérol, M., Winfree, K. B., Carter, G. C., Cui, Z. L., Bowman, L., & Garon, E. B. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.001 · Cited by 11
Self-citation
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
Besse, B., Barlési, F., Demedts, I., Pradera, J. F., Robinet, G., Gazzah, A., Soldatenkova, V., Frimodt‐Moller, B., Kim, J. S., & Vansteenkiste, J. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.002 · Cited by 11
Self-citation
The Role of the VEGF Signaling Pathway in Tumor Angiogenesis
Ferrara, N. (2019) · Springer eBooks · doi:10.1007/978-3-319-33673-2_3 · Cited by 13
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study
Zhao, Y., Wang, Q., Zhang, L., Shi, J., Wang, Z., Cheng, Y., He, J., Shi, Y., Chen, W., Luo, Y., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-320 · Cited by 10
The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer
Tanvetyanon, T., Creelan, B., & Antonia, S. J. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1220836 · Cited by 11
Is the Chemotherapy Era in Advanced Non-Small Cell Lung Cancer Really Over? Maybe not Yet
Russo, G. L., Imbimbo, M., & Garassino, M. C. (2016) · Tumori Journal · doi:10.5301/tj.5000479 · Cited by 11
Monoclonal Antibodies: A Prospective and Retrospective View
Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200219142231 · Cited by 14
Real-World Treatment Patterns and Clinical Outcomes After Platinum-Doublet Chemotherapy and Immunotherapy in Metastatic Non–Small Cell Lung Cancer: A Multiregional Chart Review in the United States, Europe, and Japan
Leal, T. A. B., Dasgupta, A., Latrémouille-Viau, D., Rossi, C., Rai, P., Barlési, F., & Liu, S. V. (2024) · JCO Global Oncology · doi:10.1200/go.23.00483 · Cited by 10
Targeted Therapies, Novel Antibodies, and Immunotherapies in Advanced Non–Small Cell Lung Cancer: Clinical Evidence and Drug Approval Patterns
Koban, M. U., Hartmann, M., Amexis, G., Franco, P., Huggins, L., Shah, I., & Karachaliou, N. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0741 · Cited by 10
Comprehensive insights into systemic therapy for the whole-course management of hepatocellular carcinoma
Jiang, J., Feng, K., Zhang, L., & Ma, K. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000086 · Cited by 10
Opening Windows into Tumors
Simberg, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b05161 · Cited by 10
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
Park, S., Langley, E. J., Sun, J., Lockton, S., Ahn, J. S., Jain, A., Park, K., Singh, S., Kim, P., & Ahn, M. (2015) · Oncotarget · doi:10.18632/oncotarget.5131 · Cited by 10
Self-citation
Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials
Gao, Q., Zhao, L., Li, W., Zhang, H., Hou, N., & Guo, L. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s88102 · Cited by 10
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non–Small-Cell Lung Cancer
Garon, E. B., Reck, M., Paz-Ares, L. G., Ponce, S., Jaime, J. C., Juan, Ó., Nadal, E., Lee, P., Dalal, R. P., Liu, J., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.023 · Cited by 10
Self-citation
Targeting the angio-proteostasis network: Combining the forces against cancer
Devisscher, L., Vieri, M., Logue, S. E., Panse, J., Geerts, A. M., Vlierberghe, H. V., Chevet, É., Gorman, A. M., Samali, A., & Masouleh, B. K. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.007 · Cited by 10
Data Integration to Improve Real-world Health Outcomes Research for Non–Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration
Grabner, M., Molife, C., Wang, L., Winfree, K. B., Cui, Z. L., Carter, G. C., & Hess, L. M. (2021) · JMIR Cancer · doi:10.2196/23161 · Cited by 10
Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial
Shen, Y., Lü, J., Hu, F., Qian, J., Zhang, X., Zhong, R., Zhong, H., Chu, T., & Han, B. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03964-9 · Cited by 10
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study
Kawachi, H., Tamiya, M., Matsumoto, K., Tamiya, A., Yanase, T., Tanizaki, S., & Kumagai, T. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01214-w · Cited by 10
Current status and future of anti-angiogenic drugs in lung cancer
Yan, X., Zhao, Z., & Tang, H. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01039-8 · Cited by 10
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer
Siringo, M., Baena, J., Bote, H., Torres-Jiménez, J., Zurera, M. C., Zugazagoitia, J., & Paz-Ares, L. G. (2023) · Cancers · doi:10.3390/cancers15235505 · Cited by 10
Beyond Adenocarcinoma: Current Treatments and Future Directions for Squamous, Small Cell, and Rare Lung Cancer Histologies
Gerber, D. E., Paik, P. K., & Dowlati, A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.147 · Cited by 10
Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis
Abdel-Rahman, O. M., & Elhalawani, H. M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1074677 · Cited by 10
Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far
He, B., Xu, Y., Ding, V. W., Zhang, H., Zhang, X., & Jablons, D. M. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s92996 · Cited by 13
The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update
Matikas, A., Georgoulias, V., & Kotsakis, A. P. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1240620 · Cited by 10
Survival Gains from First-Line Systemic Therapy in Metastatic Non-Small Cell Lung Cancer in the U.S., 1990–2015: Progress and Opportunities
Roth, J. A., Goulart, B. H. L., Ravelo, A., Kolkey, H., & Ramsey, S. D. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0253 · Cited by 10
Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC
Langhammer, S., & Scheerer, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16674 · Cited by 9
Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy
Kotake, M., Miura, Y., Imai, H., Mori, K. P., Sakurai, R., Kaira, K., Tomizawa, Y., Minato, K., Saito, R., & Hisada, T. (2017) · Chemotherapy · doi:10.1159/000456534 · Cited by 10
Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
Cobo, M., Gutiérrez, V., Villatoro, R., Trigo, J. M., García, I. R., Lopez, O., Ruiz, M., Godoy-Ortíz, A., López, I., & Varela, M. A. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s118996 · Cited by 10
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancer
Kato, Y. X., Okuma, Y., Watanabe, K., Yomota, M., Kawai, S., Hosomi, Y., & Okamura, T. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03843-0 · Cited by 10
A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer
Zhou, T., Wu, C., Zhang, C., Li, P., Dong, H., Zhou, X., Lu, H., Qi, C., & Ling, Y. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.05.33 · Cited by 10
Non-small Cell Lung Cancer
Tantraworasin, A., Kongkarnka, S., Lertprasertsuke, N., Wannasopha, Y., Euathrongchit, J., Suksombooncharoen, T., Saeteng, S., Siwachat, S., & Chewaskulyong, B. (2019) · Springer eBooks · doi:10.1007/978-3-030-16245-0_9 · Cited by 10
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy
Garon, E. B., Scagliotti, G. V., Gautschi, O. P., Reck, M., Thomas, M., Docampo, L. I., Kalofonos, H. P., Kim, J.-H., Gans, S. J. M., Brustugun, O. T., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000567 · Cited by 11
Self-citation
Value of TTF‑1 expression in non‑squamous non‑small‑cell lung cancer for assessing docetaxel monotherapy after chemotherapy failure
Takeuchi, A., Oguri, T., Yamashita, Y., Sone, K., Fukuda, S., Takakuwa, O., Uemura, T., Maeno, K., Inoue, Y., Yamamoto, S., et al. (2020) · Molecular and Clinical Oncology · doi:10.3892/mco.2020.2080 · Cited by 10
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA
Remón, J., Lacas, B., Herbst, R. S., Reck, M., Garon, E. B., Scagliotti, G. V., Ramlau, R., Hanna, N. H., Vansteenkiste, J., Yoh, K., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.002 · Cited by 10
Self-citation
Medical management of older patients with lung cancer
Zenke, Y., Hakozaki, T., Nakahara, Y., Horinouchi, H., Ohe, Y., & Barber, J. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac135 · Cited by 10
Focus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLC
Tran, P. N., & Klempner, S. J. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00065 · Cited by 10
Risk of hypertension with ramucirumab-based therapy in solid tumors: data from a literature based meta-analysis
Roviello, G., Pacifico, C., Corona, P., & Generali, D. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0452-1 · Cited by 10
Apatinib inhibits macrophage-mediated epithelial–mesenchymal transition in lung cancer
Liu, S., Su, L., Mu, X., Shi, Y., Zhang, A., & Ge, X. (2018) · RSC Advances · doi:10.1039/c8ra01231h · Cited by 10
Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non–squamous Non–small Cell Lung Cancer After Progression on Platinum and Pemetrexed
Ciunci, C. A., Reibel, J. B., Evans, T. L., Mick, R., Bauml, J. M., Aggarwal, C., Marmarelis, M. E., Singh, A. P., D’Avella, C. A., Cohen, R. B., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.02.004 · Cited by 9
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic Non–Small Cell Lung Cancer and Metastatic Cutaneous Melanoma
Lee, S. M., Hamid, O., Jotte, R. M., Zakharia, Y., Medina, T. M., Gillespie-Twardy, A. L., Mehmi, I., Chandra, S., Watson, G. T., Ward, P. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1478 · Cited by 9
Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis
Hetta, ‏. F., Alqifari, S. F., Alshehri, K., Alhowiti, A., Alharbi, S. S., Mirghani, H. O., Alrasheed, T., Mostafa, M. E. A., Sheikh, M., Elodemi, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050652 · Cited by 9
Angiogenesis and lung cancer: ramucirumab prolongs survival in 2(nd)-line metastatic NSCLC.
Das, M. S., & Wakelee, H. A. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.09.05 · Cited by 9
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer.
Pilotto, S., Carbognin, L., Karachaliou, N., Garassino, M. C., Cuppone, F., Petraglia, S., Rosell, R., Tortora, G., & Bria, E. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.10.08 · Cited by 9
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies
Santoni, M., Conti, A., Massari, F., Nunno, V. D., Faloppi, L., Galizia, G., Morbiducci, J., Piva, F., Buti, S., Iacovelli, R., et al. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1704626 · Cited by 9
Potential of VEGFR2 expression as a predictive marker of PD‑1 blockade in patients with advanced NSCLC
Kaira, K., Imai, H., Kawasaki, T., Hashimoto, K., Miura, Y., Shiono, A., Yamaguchi, O., Mouri, A., Kobayashi, K., Yasuda, M., et al. (2022) · Oncology Reports · doi:10.3892/or.2022.8429 · Cited by 9
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
Yang, J. C., Zhou, C., Janne, P. A., Ramalingam, S. S., Kim, T. M., Riely, G. J., Spira, A. I., Piotrowska, Z., Mekhail, T. M., Campelo, M. R. G., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2157815 · Cited by 9
Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms
Schütte, W., Gutz, S., Nehls, W., Blum, T. G., Brückl, W. M., Buttmann‐Schweiger, N., Büttner, R., Christopoulos, P., Delis, S., Deppermann, K.-M., et al. (2023) · Pneumologie · doi:10.1055/a-2029-0134 · Cited by 11
Self-citation
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis
Luo, W. P., Zhu, J., Zhang, W., Yu, A., Zhou, W., & Xu, K. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2282606 · Cited by 10
Pan-cancer assessment of antineoplastic therapy-induced interstitial lung disease in patients receiving subsequent therapy immediately following immune checkpoint blockade therapy
Kitahara, Y., Inoue, Y., Yasui, H., Karayama, M., Suzuki, Y., Hozumi, H., Furuhashi, K., Enomoto, N., Fujisawa, T., Funai, K., et al. (2024) · Respiratory Research · doi:10.1186/s12931-024-02683-8 · Cited by 9
Clinical utility of ramucirumab in advanced gastric cancer
Zalcberg, J. R., Chan, M. M. K., & Sjoquist, K. M. (2015) · Biologics · doi:10.2147/btt.s62777 · Cited by 9
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy
Manegold, C., Adjei, A. A., Bussolino, F., Cappuzzo, F., Crinò, L., Dziadziuszko, R., Ettinger, D. S., Fennell, D. A., Kerr, K. M., Chevalier, T. L., et al. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000118 · Cited by 8
Self-citation
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
Gaschler‐Markefski, B., Sikken, P., Heymach, J. V., Gottfried, M., Mellemgaard, A., Novello, S., Gann, C.-N., Barrueco, J., Reck, M., Hanna, N. H., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000102 · Cited by 9
Self-citation
Response Assessment of 68Ga-DOTA-E-[c(RGDfK)]2 PET/CT in Lung Adenocarcinoma Patients Treated with Nintedanib Plus Docetaxel
Arrieta, O. G., García-Pérez, F. O., Michel-Tello, D., Ramírez-Tirado, L.-A., Pitalúa-Cortés, Q., Cruz‐Rico, G., Macedo-Pérez, E. O., Cardona, A. F., & de la Garza-Salazar, J. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.192393 · Cited by 9
Self-citation
Risk Factors for Febrile Neutropenia Induced by Docetaxel Chemotherapy in Patients with Non-small Cell Lung Cancer
Uchida, M., Yamaguchi, Y., Hosomi, S., Ikesue, H., Mori, Y., Maegawa, N., Takano, A., Sato, Y., Hosohata, K., Muroi, N., et al. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b20-00266 · Cited by 9
Efficacy and safety of S ‐1 monotherapy in previously treated elderly patients (aged ≥75 years) with non‐small cell lung cancer: A retrospective analysis
Imai, H., Minemura, H., Kishikawa, T., Yamada, Y., Suzuki, K., Umeda, Y., Wasamoto, S., Kasahara, N., Ishihara, S., Yamaguchi, O., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13622 · Cited by 9
Severe skin toxicity during whole-brain radiotherapy, targeted therapy, and additional drug intake including St. John’s wort skin oil
Eichkorn, T., Schunn, F., Regnery, S., Shafie, R. A. E., Hörner‐Rieber, J., Adeberg, S., Herfarth, K. K., Debus, J., & König, L. (2021) · Strahlentherapie und Onkologie · doi:10.1007/s00066-020-01739-0 · Cited by 9
Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study
Lü, S., Zhou, J., Niu, X., Zhou, J., Jian, H., Yin, H., Guan, S., Wang, L., Li, K., He, J., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1028 · Cited by 9
Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
Nishimura, T., Fujimoto, H., Okano, T., Naito, M., Tsuji, C., Iwanaka, S., Sakakura, Y., Yasuma, T., D’Alessandro‐Gabazza, C. N., Oomoto, Y., et al. (2022) · Cancers · doi:10.3390/cancers14122970 · Cited by 9
Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options
Leal, J. L., & John, T. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.08.009 · Cited by 9
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
Gálffy, G., Lugowska, I., Poddubskaya, E. V., Cho, B. C., Ahn, M., Han, J., Su, W.-P., Hauke, R. J., Dyar, S., Lee, D. H., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101173 · Cited by 11
Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer
Jin, S., Yang, Y., Yang, B., Zhao, Y., Ma, Y., Hong, S., Zhang, Y., Zhao, H., Huang, Y., & Zhang, L. (2015) · Medicine · doi:10.1097/md.0000000000001282 · Cited by 9
International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes
de Marinis, F., Bria, E., Ciardiello, F., Crinò, L., Douillard, J.-Y., Griesinger, F., Lambrechts, D., Pérol, M., Ramalingam, S. S., Smit, E. F., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.015 · Cited by 9
(99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.
Chen, B., Zhao, G., Ma, Q., Ji, B., Ji, T., Hua, X., & Gao, S. (2015) · PubMed Central · Cited by 9
Genitourinary tumours in the targeted therapies era
Messina, C. G. M., Buzzatti, G., Dellepiane, C., Cavo, A., Tolomeo, F., Cattrini, C., & Boccardo, F. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000405 · Cited by 9
Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis
Tian, R., Yan, H., Zhang, F., Sun, P., Zheng, X., Zhu, Y., Wáng, Q., & He, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11097 · Cited by 9
Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer
Skouras, V. S., Maragkos, C., Grapsa, D., & Syrigos, K. N. (2016) · BioDrugs · doi:10.1007/s40259-016-0194-1 · Cited by 10
Self-citation
Emerging challenges of advanced squamous cell lung cancer
Zhang, Y., Zhou, Q. H., & Wu, Y.-L. L. C. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000129 · Cited by 9
Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
Connock, M. J., Armoiry, X., Tsertsvadze, A., Meléndez‐Torres, G. J., Royle, P., Andronis, L., & Clarke, A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5507-6 · Cited by 9
Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens
Falvo, P., Orecchioni, S., Roma, S., Raveane, A., & Bertolini, F. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200817104912 · Cited by 9
Monoclonal Serotherapy
Bast, R. C., Zalutsky, M. R., & Frankel, A. E. (2017) · Wiley eBooks · doi:10.1002/9781119000822.hfcm065 · Cited by 9
Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
Zhang, C., Chen, J., Wu, H., Wang, J., Gao, L., Zhao, J., Sun, Y., Jia, Z., Mu, X., Bai, C., et al. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.02.001 · Cited by 8
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer
Lui, K., Cheung, K., Ng, W. W. M., Wang, Y., Au, D. W. H., & Cho, W. C. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211954 · Cited by 9
The tumor ecosystem: Rewiring an open, systemically integrated network for therapeutic gain
Chiodelli, P., Papait, A., Agoni, L., Quaglia, F., Silini, A. R., & Parolini, O. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119047 · Cited by 10
Real-World Efficacy of Docetaxel Plus Nintedanib After Chemo-Immunotherapy Failure in Advanced Pulmonary Adenocarcinoma
Metzenmacher, M., Rizzo, F., Kambartel, K.-O., Panse, J., Schaufler, D., Scheffler, M., Azeh, I. T., Hoiczyk, M., Turki, A. T., Atz, J., et al. (2021) · Future Oncology · doi:10.2217/fon-2021-0424 · Cited by 8
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
Tanimura, K., Uchino, J., Kimura, H., Hiranuma, O., Chihara, Y., Tanzawa, S., Takumi, C., Kita, T., Inoue, K., Minato, K., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad013 · Cited by 8
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel, D., Kim, J., & Ou, S. I. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s403614 · Cited by 8
Self-citation
Real-world outcomes in patients with KRAS G12C–mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
Gray, J. E., Hsu, H., Younan, D., Suri, G., Chia, V., Spira, A. I., & Johnson, M. L. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107260 · Cited by 8

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design
Garon, E. B., Cao, D., Alexandris, E., John, W. J., Yurasov, S., & Pérol, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.007 · Cited by 40
Self-citation
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
Pérol, M., Ciuleanu, T., Arrieta, O. G., Prabhash, K., Syrigos, K. N., Göksel, T., Park, K., Kowalyszyn, R. D., Pikiel, J., Czyżewicz, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba8006 · Cited by 17
Self-citation
A multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis
Prabhash, K., Doval, D. C., Rangarajan, B., Somani, N., Pruthi, A., Dyachkova, Y., & Puri, T. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_159_21 · Cited by 3
Self-citation
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Yoh, K., Hosomi, Y., Kasahara, K., Yamada, K., Takahashi, T., Yamamoto, N., Nishio, M., Ohe, Y., Koue, T., Nakamura, T., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.019 · Cited by 110
Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
Bidoli, P., Cappuzzo, F., Favaretto, A. G., Alabiso, O., Tiseo, M., Chella, A., Gebbia, V., Pizzuti, L., Paz-Ares, L. G., Pérol, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv343.04 · Cited by 2
Self-citation

See all

Authors: Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., Czyzewicz, G., Orlov, S. V., Lewanski, C. R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.-H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Yurasov, S., & Pérol, M.
Affiliations: University of California, Los Angeles (US)
Iuliu Hațieganu University of Medicine and Pharmacy (RO)
Instituto Nacional de Cancerología (MX)
Tata Memorial Hospital (IN)
Sotiria General Hospital (GR)
Samsung Medical Center (KR)
Russian Cancer Research Center NN Blokhin (RU)
Charing Cross Hospital (GB)
University Hospital Heidelberg (DE)
Azienda Ospedaliera San Gerardo (IT)
Cancer Center of Kansas (US)
Gemeinschaftskrankenhaus Herdecke (DE)
Yonsei University Health System (KR)
Institutul Oncologic Bucuresti (RO)
City Clinical Oncology Center (RU)
German Center for Lung Research (DE)
Ospedale di Livorno (IT)
Eli Lilly (United States) (US)
Corresponding author: Garon, Edward B
ORCID: Garon, Edward B
Ciuleanu, Tudor-Eliade
Arrieta, Oscar
Prabhash, Kumar
Park, Keunchil
Gorbunova, Vera
Pikiel, Joanna
Thomas, Michael
Dakhil, Shaker
Kim, Joo-Hang
Grigorescu, Alexandru
Reck, Martin
Cappuzzo, Federico
Sashegyi, Andreas
Yurasov, Sergey
Venue: The Lancet
Publisher: Elsevier BV
Published: 2014-08
Volume: 384
Issue: 9944
Pages: 665-673
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(14)60845-x
OpenAlex: W2140980839
Cited by: 1,309
References: 35
Citations by year: 2026: 57 · 2025: 71 · 2024: 116 · 2023: 102 · 2022: 110 · 2021: 97 · 2020: 108 · 2019: 102 · 2018: 106 · 2017: 148 · 2016: 155 · 2015: 115 · 2014: 19
FWCI: 116.89
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ramucirumab, docetaxel, non-small cell lung cancer, second-line therapy, VEGFR-2 inhibition, anti-angiogenic therapy, overall survival, progression-free survival, adverse events, drug safety, maintenance therapy, lung squamous cell carcinoma, non-squamous cell lung cancer
MeSH terms: Docetaxel, Ramucirumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Platinum, Quality of Life, Survival Rate, Disease Progression, Taxoids, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks